Harvard Bioscience (HBIO) Finished Goods (2011 - 2026)

Harvard Bioscience (HBIO) has 16 years of Finished Goods data on file, last reported at $5.5 million in Q1 2026.

• On a quarterly basis, Finished Goods rose 7.37% year-over-year to $5.5 million in Q1 2026; TTM through Mar 2026 was $5.5 million, a 7.37% increase from a year earlier, with the FY2025 full-year figure at $5.4 million, up 2.85% from the prior year.
• Finished Goods for Q1 2026 stood at $5.5 million, up from $5.4 million in the prior quarter.
• Over the last five years, Finished Goods for HBIO reached as high as $6.8 million in Q1 2022 and fell as low as $4.8 million in Q3 2024.
• Historically, Finished Goods has averaged $5.6 million across 5 years, with a median of $5.5 million in 2024.
• Across the five-year window, Finished Goods soared 32.93% in 2022 and retreated 24.33% in 2023, its largest moves.
• Year by year, Finished Goods stood at $5.2 million in 2022, then declined by 1.97% to $5.1 million in 2023, then advanced by 1.99% to $5.2 million in 2024, then rose by 2.85% to $5.4 million in 2025, then climbed by 2.51% to $5.5 million in 2026.
• Per Business Quant data, the three most recent Finished Goods figures were $5.5 million in Q1 2026, $5.4 million in Q4 2025, and $5.9 million in Q3 2025.